论文部分内容阅读
慢性粒细胞白血病(CML)发病机制较为明确,对其癌蛋白BCR-ABL的研究也较为透彻,因而常被作为肿瘤分子靶向治疗的研究模型。现就CML治疗新药研究进展及BCR-ABL基因检测技术进行综述。
The pathogenesis of chronic myeloid leukemia (CML) is relatively clear, and its oncoprotein BCR-ABL is also studied thoroughly. Therefore, it is often used as a research model for tumor molecular targeted therapy. Now on the CML treatment of new drug research progress and BCR-ABL gene detection technology are reviewed.